NCT01081938 - Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

INSULIN GLARGINE

"Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine"

DRUG

INSULIN GLULISINE

"Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine"

Trial Locations (10)

30150-120

Sanofi-Aventis Investigational Site Number 076-007, Belo Horizonte

80420-011

Sanofi-Aventis Investigational Site Number 076-011, Curitiba

Unknown

Sanofi-Aventis Investigational Site Number 076-005, Joinville

90035-001

Sanofi-Aventis Investigational Site Number 076-001, Porto Alegre

90035-003

Sanofi-Aventis Investigational Site Number 076-004, Porto Alegre

15090-000

Sanofi-Aventis Investigational Site Number 076-006, São José do Rio Preto

01232-010

Sanofi-Aventis Investigational Site Number 076-010, São Paulo

01308-050

Sanofi-Aventis Investigational Site Number 076-008, São Paulo

01323-020

Sanofi-Aventis Investigational Site Number 076-003, São Paulo

01323-900

Sanofi-Aventis Investigational Site Number 076-009, São Paulo